Individual results vary based on skin condition, metabolism, wellness goals, existing pigmentation concerns, and adherence to the recommended treatment plan
For example: Semaglutide (Ozempic, Wegovy): The SmPC (available on the Electronic Medicines Compendium, EMC) specifies storage at 2C to 8C before first use, with defined in-use stability periods at room temperature after first use
Dose Group GI Adverse Events (%) Nausea (%) Abdominal Discomfort/Pain Placebo 32.6% 11.6% Low baseline 1 mg 48.6% ~20% Mild, infrequent 4 mg (escalated) 60.0% ~30% Moderate increase 8 mg (escalated) 57.5% ~38% Present in dose-escalation phase 12 mg (escalated) 66.7% 45.8% Highest incidence, mostly transient Source: Jastreboff AM, Kaplan LM, Fras JP, et al
Final Perspective The January 2026 launch of oral Wegovy represents an expansion of FDA-approved options for patients seeking medically-supervised weight management
Perfect for on-the-go touch-ups
Age, activity level, and baseline metabolism also inform dosing decisions